Echopoint Medical Ltd, a London, UK-based medtech company, raised £2.8M in funding.
Backers included Parkwalk, the UCL Technology Fund and two grants from Innovate UK.
The company intends to use the funds to to further develop the optical fibre sensors on its microcatheters, as well as its technology platform which translates their ultrasound signals into meaningful metrics.
A spinout company from UCL, Echopoint Medical has developed technology that aims to help Coronary heart disease disease patients in a ‘grey zone’ where the need for treatment is unclear.
The company’s microcatheters, which use fibre-optic sensors to accurately measure blood pressure and flow, aim to enable clinicians to precisely assess patients and dramatically reduce stent implants.
Echopoint was founded in November 2018 and is led by:
– executive chairman Antony Odell;
– Dr Adrien Desjardins, Chief Technical Officer and a senior lecturer in the Department of Medical Physics at UCL; and
– Dr Malcolm Finlay, Chief Medical Officer and a consultant cardiologist at Barts Heart Centre.